enfortumab vedotin

Drug Overview

Enfortumab vedotin is a groundbreaking medication used primarily to treat advanced bladder cancer. It is considered a Targeted Therapy and is frequently referred to as a “Smart Drug” because of its ability to find and destroy cancer cells while causing less damage to healthy parts of the body.

Technically, this drug is an Antibody-Drug Conjugate (ADC). You can think of it as a “guided missile.” The medication has a “gps” part that finds the cancer and a “payload” part that carries the medicine to kill it.

• Generic Name: Enfortumab vedotin-ejfv
• US Brand Names: Padcev®
• Drug Class: Antibody-Drug Conjugate (ADC); Nectin-4 directed antibody
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA-Approved for specific types of advanced or metastatic urothelial cancer.
  
  Learn about enfortumab vedotin in targeted therapy. Our hospital integrates holistic wellness and advanced medicine to aid patients in their recovery.

What Is It and How Does It Work? (Mechanism of Action)

Enfortumab vedotin is a Targeted Therapy designed to attack cancer cells that have a specific protein on their surface called Nectin-4. In bladder cancer, almost all cancer cells have a lot of Nectin-4, while healthy cells have very little.

The drug works through a precise four-step molecular process:

1. Search and Attach: The antibody portion of the drug travels through the blood until it finds the Nectin-4 protein on a cancer cell. It latches onto the cell like a key in a lock.
2. Entry: Once attached, the cancer cell pulls the drug inside its own body (a process called internalization).
3. Release of the Medicine: Inside the cell, the “linker” that holds the drug together is broken down by the cell’s enzymes. This releases the active medicine, a powerful chemical called MMAE (monomethyl auristatin E).
4. Cell Destruction: MMAE is a “microtubule-disrupting agent.” It stops the cell from being able to divide or grow. This causes the cancer cell to break apart and die (apoptosis).

FDA Approved Clinical Indications

Enfortumab vedotin is approved for adult patients with advanced bladder cancer (urothelial cancer) in the following scenarios:

Oncological Uses:

• First-Line Treatment: Combined with pembrolizumab (an immunotherapy) for patients with metastatic bladder cancer.
• Previously Treated Cancer: For patients whose cancer has spread and who have already received chemotherapy (platinum-based) and immunotherapy (PD-1/L1 inhibitors).
• Ineligible for Chemotherapy: For patients who cannot receive certain types of chemotherapy (cisplatin) and have already tried at least one other treatment.

Non-oncological Uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

This medication is given as an infusion into a vein by a healthcare professional.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Patients with moderate or severe liver issues should not use this drug. Mild liver issues require close monitoring.
• Renal (Kidney) Insufficiency: No specific starting dose adjustment is needed for kidney issues, but patients are monitored for side effects.
• Side Effects: If a patient develops a severe rash or nerve pain, the doctor may lower the dose or pause the treatment.

Clinical Efficacy and Research Results

Recent clinical trials (2020–2025) have shown that enfortumab vedotin is highly effective, especially when used as a first treatment.

• Overall Survival (OS): In the landmark EV-302 study (results updated 2023-2024), patients receiving enfortumab vedotin combined with pembrolizumab lived nearly twice as long as those on standard chemotherapy (31.5 months versus 16.1 months).
• Disease Progression: The same study showed that the risk of the cancer getting worse was reduced by 53% compared to chemotherapy.
• Response Rate: Approximately 68% of patients saw their tumors shrink when using the combination therapy, with many seeing the cancer disappear completely on scans.

Safety Profile and Side Effects

Black Box Warning: Severe Skin Reactions

This drug can cause very serious skin reactions (like Stevens-Johnson syndrome). If you notice a new or worsening rash, blistering, or peeling skin, you must contact your doctor immediately.

Common Side Effects (>10%):

• Rash and Itching: Dry or red skin is very common.
• Peripheral Neuropathy: Numbness, tingling, or “pins and needles” in the hands and feet.
• Fatigue: Feeling unusually tired or weak.
• Hair Loss (Alopecia): Thinning or loss of hair.
• Changes in Taste: Foods may taste different or metallic.
• Diarrhea and Nausea: General stomach upset.

Serious Adverse Events:

• Hyperglycemia: Very high blood sugar levels (even in patients without diabetes).
• Pneumonitis: Inflammation of the lungs causing trouble breathing.
• Eye Issues: Dry eyes or changes in vision.

Management Strategies: Doctors often suggest using preservative-free artificial tears for dry eyes and thick moisturizers for the skin. If nerve pain occurs, the dose is often lowered to prevent permanent damage.

Research Areas

Enfortumab vedotin is currently a major focus in Immunotherapy research. Because it kills cancer cells in a way that “wakes up” the immune system, scientists are finding it works even better when paired with immune-boosting drugs. Current research is also looking at using this drug before surgery (neoadjuvant therapy) to shrink tumors and make surgery more successful for patients with muscle-invasive bladder cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Blood Glucose: You must check your blood sugar levels before starting.
• Liver Function Tests: To ensure your liver can process the medication.
• Skin Exam: To have a baseline of your skin health.

Precautions During Treatment:

• Sun Protection: This drug can make your skin more sensitive. Avoid direct sun and use high-SPF sunscreen.
• Blood Sugar Tracking: If you have diabetes, you must monitor your sugar levels more often.
• Nerve Checks: Report any new numbness in your fingers or toes immediately.

“Do’s and Don’ts”:

• DO use thick, fragrance-free creams on your skin every day.
• DO drink plenty of water to help your kidneys.
• DON’T ignore a skin rash, even if it seems small.
• DON’T start any new medications without telling your oncologist.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Enfortumab vedotin (Padcev) is a prescription medication that must be managed by a qualified oncologist. Always seek the advice of your physician regarding your specific diagnosis and treatment. In case of a medical emergency, call your local emergency services immediately.